Deliver Your News to the World

One company is diligently preparing for the worst case H1N1 Flu scenario with promising results (AMEX: CVM)


“…Off the record, in a deep conversation in a dark bar, a government scientist researching pandemic flu would say that they’re scared to death because they see just how intelligent this virus is…”

LOS ANGELES - 07/29/09 - BioMedReports, the news portal covering the biomedical news and financial sector in a special report about the H1N1 flu pandemic is reporting that CEL-SCI Corporation (AMEX: CVM) is positioned to help combat the virus after diligently preparing for the worst case scenario with promising results.

CEL-SCI’s preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology potentially induce protection against illnesses such as the swine influenza. L.E.A.P.S. helps direct the immune response to the vaccine epitope.

“What this company’s technology proposes is the ability to attack what comes out of the Swine Flu’s mutations the moment it shows up, as opposed to what we have now,” reports M.E. Garza.

“The idea is very simple, if I’m looking for a bad guy and I know that bad guy is going to undergo facial reconstruction or hair color changes, the only way I’m going to be able to capture that bad guy is by focusing on parts of that person that cannot be changed,” explains CEL-SCI’s CEO, Geert Kersten.

While some companies like Gilead Sciences (NASDAQ:GILD), Roche (OTC:RHHBY), GlaxoSmithKline (NYSE:GSK) and others are stockpiling vaccines and other treatments, that may not be enough.

The alarming new report appears today at

Biotech investors interested in accessing the complete database of clinical trials and upcoming FDA decisions can access that information on the same site:


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.